semaglutide phase 2 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Semaglutide 7·2 mg was modestly superior to placebo and 2·4 mg (#wegovy) for #WeightLoss in adults with obesity, while retaining a favourable risk–benefit profile. We recently had the lead author on the

29.86

★★★★☆4.8 (126)

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results

23.02

★★★★★4.9 (98)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

29.51

★★★★★5.0 (157)

In this phase 2 trial in participants with obesity, treatment with bimagrumab plus semaglutide for 72 weeks resulted in substantial reductions in body weight. The safety findings were consistent with the known

23.96

★★★★★4.7 (84)

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

26.85

★★★★★4.9 (203)

Higher-Dose Semaglutide Injection Proves Mettle in Phase III Trials

26.94

★★★★★5.0 (176)

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

25.48

★★★★★4.8 (132)